IL10 and pancreatic neoplasm: In the model of advanced pancreatic cancer in situ, the survival time of mice treated with VVLΔTK-IL-10 was significantly improved to 138.5 days, compared with 69.7 days after VVLΔTK treatment (P<0.01).